Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CERS Stock Forecast 2026-2027
$2.71
Current Price
$543.00M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CERS Price Targets
+84.5%
To High Target of $5.00
+84.5%
To Median Target of $5.00
+47.6%
To Low Target of $4.00
CERS Price Momentum
-4.6%
1 Week Change
+3.8%
1 Month Change
+79.5%
1 Year Change
+31.6%
Year-to-Date Change
-14.0%
From 52W High of $3.15
+135.7%
From 52W Low of $1.15
📊 TOP ANALYST CALLS
Did CERS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cerus is one of their latest high-conviction picks.
Latest CERS Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, CERS has a bullish consensus with a median price target of $5.00 (ranging from $4.00 to $5.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $2.71, the median forecast implies a 84.5% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Mark Massaro at BTIG, suggesting a 47.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CERS Analyst Ratings
3
Buy
0
Hold
0
Sell
CERS Price Target Range
Low
$4.00
Average
$5.00
High
$5.00
Current: $2.71
Latest CERS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CERS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 1, 2026 | BTIG | Mark Massaro | Buy | Upgrade | $4.00 |
| Feb 21, 2025 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Oct 17, 2024 | Stifel | Buy | Maintains | $N/A | |
| May 3, 2024 | Cantor Fitzgerald | Overweight | Maintains | $N/A | |
| Apr 12, 2024 | Craig-Hallum | Buy | Initiates | $N/A | |
| Mar 7, 2024 | Stephens & Co. | Equal-Weight | Reiterates | $N/A | |
| Mar 6, 2024 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Nov 8, 2023 | Cantor Fitzgerald | Ross Osborn | Overweight | Assumes | $3.00 |
| Jan 20, 2023 | BTIG | Neutral | Downgrade | $N/A | |
| May 27, 2020 | Stifel | Buy | Maintains | $N/A | |
| Apr 16, 2020 | Stephens & Co. | Overweight | Maintains | $N/A | |
| Feb 26, 2020 | BTIG | Buy | Initiates | $N/A | |
| Feb 26, 2020 | BTIG Research | Buy | Initiates | $N/A | |
| Nov 13, 2019 | BTIG | Buy | Upgrade | $N/A | |
| Nov 13, 2019 | BTIG Research | Buy | Upgrade | $N/A | |
| Aug 28, 2019 | Stifel | Buy | Initiates | $N/A | |
| Apr 22, 2016 | BTIG | Buy | Maintains | $N/A | |
| Apr 22, 2016 | BTIG Research | Buy | Maintains | $N/A | |
| Dec 17, 2015 | Wedbush | Neutral | Downgrade | $N/A | |
| Apr 24, 2015 | BTIG | Buy | Initiates | $N/A |
Cerus Corporation (CERS) Competitors
The following stocks are similar to Cerus based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cerus Corporation (CERS) Financial Data
Cerus Corporation has a market capitalization of $543.00M with a P/E ratio of -33.9x. The company generates $216.56M in trailing twelve-month revenue with a -4.4% profit margin.
Revenue growth is +24.1% quarter-over-quarter, while maintaining an operating margin of -0.7% and return on equity of -15.4%.
Valuation Metrics
Market Cap
$543.00M
Enterprise Value
$560.67M
P/E Ratio
-33.9x
PEG Ratio
0.5x
Price/Sales
2.5x
Growth & Margins
Revenue Growth (YoY)
+24.1%
Gross Margin
+52.0%
Operating Margin
-0.7%
Net Margin
-4.4%
EPS Growth
+24.1%
Financial Health
Cash/Price Ratio
+14.8%
Current Ratio
1.6x
Debt/Equity
142.6x
ROE
-15.4%
ROA
-0.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cerus Corporation (CERS) Business Model
About Cerus Corporation
What They Do
Develops biomedical products for blood safety.
Business Model
The company generates revenue by selling its INTERCEPT Blood System, which is used to inactivate pathogens in blood components, thus enhancing transfusion safety. This system is approved for use in multiple regions, allowing access to a wide range of blood centers and hospitals, particularly in the U.S. and Europe.
Additional Information
Founded in 1991 and based in Concord, California, Cerus Corporation is focused on the blood safety segment and provides essential technologies that ensure safe blood availability for patients. Their innovative products, including INTERCEPT Fibrinogen Complex, address critical needs in transfusion medicine.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
614
CEO
Mr. William M. Greenman
Country
United States
IPO Year
1997
Website
www.cerus.comCerus Corporation (CERS) Latest News & Analysis
Latest News
Quick Summary
Bradley L. Radoff, a significant shareholder of Cerus Corporation (CERS), plans to withhold support for the company's director nominees at the 2026 annual meeting due to poor performance and lack of profitability.
Why It Matters
Bradley L. Radoff's decision to withhold support for Cerus' director nominees signals potential governance issues and dissatisfaction with management, which could impact stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Cerus reported Q1 2026 product revenues up 24% YoY, driven by platelet demand and IFC adoption. The company raised 2026 revenue guidance to $227-$231 million, indicating 10%-12% growth. IFC volumes increased 120% YoY.
Why It Matters
Cerus' strong Q1 revenue growth and raised guidance signal robust demand and market expansion, particularly in IFC, indicating a positive outlook for future profitability and investment potential.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Cerus Corporation (CERS) held its Q1 2026 earnings call, providing insights into financial performance and business developments. Further details can be found in the transcript.
Why It Matters
Cerus Corporation's Q1 2026 earnings call provides insights into financial performance and strategic direction, impacting investment decisions and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Cerus Corporation (Nasdaq: CERS) reported strong Q1 2026 results, driven by increased demand for INTERCEPT Fibrinogen Complex, prompting an upward revision of product revenue guidance.
Why It Matters
Cerus Corporation's strong Q1 performance and raised revenue guidance indicate positive growth prospects, potentially boosting investor confidence and stock value.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Cerus Corporation (CERS) has signed a four-year supply agreement with Établissement Français du Sang for the INTERCEPT Blood System and the INT200 illumination device.
Why It Matters
Cerus Corporation's new supply agreement with EFS enhances its revenue stability and growth potential, signaling strong demand for its blood safety technologies, which can boost investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Cerus Corporation (Nasdaq: CERS) will release its Q1 2026 financial results on April 30, 2026, after market close, followed by a conference call at 4:30 PM ET.
Why It Matters
Cerus Corporation's upcoming financial results and management discussion could influence stock performance, providing insights into its growth and future strategies, critical for investment decisions.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About CERS Stock
What is Cerus Corporation's (CERS) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Cerus Corporation (CERS) has a median price target of $5.00. The highest price target is $5.00 and the lowest is $4.00.
Is CERS stock a good investment in 2026?
According to current analyst ratings, CERS has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.71. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CERS stock?
Wall Street analysts predict CERS stock could reach $5.00 in the next 12 months. This represents a 84.5% increase from the current price of $2.71. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cerus Corporation's business model?
The company generates revenue by selling its INTERCEPT Blood System, which is used to inactivate pathogens in blood components, thus enhancing transfusion safety. This system is approved for use in multiple regions, allowing access to a wide range of blood centers and hospitals, particularly in the U.S. and Europe.
What is the highest forecasted price for CERS Cerus Corporation?
The highest price target for CERS is $5.00 from at , which represents a 84.5% increase from the current price of $2.71.
What is the lowest forecasted price for CERS Cerus Corporation?
The lowest price target for CERS is $4.00 from Mark Massaro at BTIG, which represents a 47.6% increase from the current price of $2.71.
What is the overall CERS consensus from analysts for Cerus Corporation?
The overall analyst consensus for CERS is bullish. Out of 3 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $5.00.
How accurate are CERS stock price projections?
Stock price projections, including those for Cerus Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 8, 2026 6:57 AM UTC